{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:36:44Z","timestamp":1793111804528,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2023\/50\/O\/NZ7\/00422"],"award-info":[{"award-number":["2023\/50\/O\/NZ7\/00422"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/35\/B\/NZ5\/01428"],"award-info":[{"award-number":["2019\/35\/B\/NZ5\/01428"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41375-026-03093-z","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:06:47Z","timestamp":1787144807000},"page":"2466-2480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-5677","authenticated-orcid":false,"given":"Agnieszka","family":"D\u0105bkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8703-5614","authenticated-orcid":false,"given":"Martyna","family":"Janowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Pastorczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2856-6968","authenticated-orcid":false,"given":"Krzysztof","family":"Domka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7814-5830","authenticated-orcid":false,"given":"Zuzanna","family":"Nowicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-6627","authenticated-orcid":false,"given":"Zuzanna","family":"Urbanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Zaj\u0105c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8043-0716","authenticated-orcid":false,"given":"Miko\u0142aj","family":"Bugajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4600-5909","authenticated-orcid":false,"given":"Julia","family":"Grzybowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8199-2263","authenticated-orcid":false,"given":"Pola","family":"Pruchniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudyna","family":"Fidyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Taslim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-6763","authenticated-orcid":false,"given":"Nicholas T.","family":"Crump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-7253","authenticated-orcid":false,"given":"Alexey","family":"Ushmorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Patkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-5233","authenticated-orcid":false,"given":"Malgorzata","family":"Firczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"3093_CR1","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1200\/JCO.23.01286","volume":"41","author":"R Pieters","year":"2023","unstructured":"Pieters R, Mullighan CG, Hunger SP. Advancing diagnostics and therapy to reach universal cure in childhood ALL. J Clin Oncol. 2023;41:5579\u201391.","journal-title":"J Clin Oncol"},{"key":"3093_CR2","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1891\u2013902.","journal-title":"Blood"},{"key":"3093_CR3","doi-asserted-by":"crossref","unstructured":"Ravich JW, Huang S, Zhou Y, Brown P, Pui CH, Inaba H, et al. Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel. Transpl Cell Ther. 2022;73.e1-73.e9","DOI":"10.1016\/j.jtct.2021.11.019"},{"key":"3093_CR4","doi-asserted-by":"publisher","first-page":"e008213","DOI":"10.1136\/jitc-2023-008213","volume":"12","author":"E Mikhailova","year":"2024","unstructured":"Mikhailova E, Popov A, Roumiantseva J, Budanov O, Lagoyko S, Zharikova L, et al. Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL. J Immunother Cancer. 2024;12:e008213.","journal-title":"J Immunother Cancer"},{"key":"3093_CR5","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"3093_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Acute Lymphoblastic Leukemia. 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed 29 Jul 2025."},{"key":"3093_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/cytob.21176","volume":"86","author":"S\u0119dek","year":"2014","unstructured":"S\u0119dek, Bulsa J, Sonsala A, Twardoch M, Wieczorek M, Malinowska I, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: How different are they from their normal counterparts?. Cytom B Clin Cytom. 2014;86:329\u201339.","journal-title":"Cytom B Clin Cytom"},{"key":"3093_CR8","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105:1494\u2013506.","journal-title":"Haematologica"},{"key":"3093_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1309\/AJCP8G5RMTWUEMUU","volume":"132","author":"AC Seegmiller","year":"2009","unstructured":"Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol. 2009;132:940\u20139.","journal-title":"Am J Clin Pathol"},{"key":"3093_CR10","doi-asserted-by":"publisher","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","volume":"115","author":"JF Li","year":"2018","unstructured":"Li JF, Dai YT, Lilljebj\u00f6rn H, Shen SH, Cui BW, Bai L, et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U A. 2018;115:E11711.","journal-title":"Proc Natl Acad Sci U A"},{"key":"3093_CR11","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1200\/JCO.23.02238","volume":"42","author":"TC Chang","year":"2024","unstructured":"Chang TC, Chen W, Qu C, Cheng Z, Hedges D, Elsayed A, et al. Genomic determinants of outcome in acute lymphoblastic leukemia. J Clin Oncol. 2024;42:3491\u2013503.","journal-title":"J Clin Oncol"},{"key":"3093_CR12","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.7150\/jca.33989","volume":"10","author":"Q Han","year":"2019","unstructured":"Han Q, Ma J, Gu Y, Song H, Kapadia M, Kawasawa YI, et al. RAG1 high expression associated with IKZF1 dysfunction in adult B-cell acute lymphoblastic leukemia. J Cancer. 2019;10:3842\u201350.","journal-title":"J Cancer"},{"key":"3093_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41418-023-01212-2","volume":"32","author":"M Affar","year":"2025","unstructured":"Affar M, Bottardi S, Quansah N, Lemari\u00e9 M, Ram\u00f3n AC, Affar EB, et al. IKAROS: from chromatin organization to transcriptional elongation control. Cell Death Differ. 2025;32:37\u201355.","journal-title":"Cell Death Differ"},{"key":"3093_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/blood.2024024787","volume":"145","author":"T Zhang","year":"2025","unstructured":"Zhang T, Wang Y-F, Montoya A, Patrascan I, Nebioglu N, Pallikonda HA, et al. Conserved helical motifs in the IKZF1 disordered region mediate NuRD interaction and transcriptional repression. Blood. 2025;145:422\u201337.","journal-title":"Blood"},{"key":"3093_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1084\/jem.20160049","volume":"214","author":"H Schjerven","year":"2017","unstructured":"Schjerven H, Ayongaba EF, Aghajanirefah A, McLaughlin J, Cheng D, Geng H, et al. Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL. J Exp Med. 2017;214:793\u2013814.","journal-title":"J Exp Med"},{"key":"3093_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/1878-0261.12476","volume":"13","author":"K Fidyt","year":"2019","unstructured":"Fidyt K, Pastorczak A, Goral A, Szczygiel K, Fendler W, Muchowicz A, et al. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia. Mol Oncol. 2019;13:1180\u201395.","journal-title":"Mol Oncol"},{"key":"3093_CR17","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.3324\/haematol.2023.284853","volume":"109","author":"K Domka","year":"2024","unstructured":"Domka K, D\u0105bkowska A, Janowska M, Urba\u0144ska Z, Pastorczak A, Winiarska M, et al. Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models. Haematologica. 2024;109:3520\u201332.","journal-title":"Haematologica"},{"key":"3093_CR18","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1182\/blood-2017-10-813576","volume":"131","author":"F Wang","year":"2018","unstructured":"Wang F, Demir S, Gehringer F, Osswald CD, Seyfried F, Enzenm\u00fcller S, et al. Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:2929\u201342.","journal-title":"Blood"},{"key":"3093_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1084\/jem.20160048","volume":"214","author":"MT Witkowski","year":"2017","unstructured":"Witkowski MT, Hu Y, Roberts KG, Boer JM, McKenzie MD, Liu GJ, et al. Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome. J Exp Med. 2017;214:773\u201391.","journal-title":"J Exp Med"},{"key":"3093_CR20","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1182\/blood.2019002655","volume":"136","author":"C Song","year":"2020","unstructured":"Song C, Ge Z, Ding Y, Tan B-H, Desai D, Gowda K, et al. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. Blood. 2020;136:1520\u201334.","journal-title":"Blood"},{"key":"3093_CR21","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 2017;171."},{"key":"3093_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929\u201335.","journal-title":"Science"},{"key":"3093_CR23","doi-asserted-by":"crossref","unstructured":"Pyrzynska B, Dwojak M, Zerrouqi A, Morlino G, Zapala P, Miazek N, et al. FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology 2018;7.","DOI":"10.1080\/2162402X.2017.1423183"},{"key":"3093_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.cell.2017.09.045","volume":"171","author":"F Langlet","year":"2017","unstructured":"Langlet F, Haeusler RA, Lind\u00e9n D, Ericson E, Norris T, Johansson A, et al. Selective inhibition of FOXO1 activator\/repressor balance modulates hepatic glucose handling. Cell. 2017;171:824\u2013.e18.","journal-title":"Cell"},{"key":"3093_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, Sheen J-H, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell. 2006;22:159\u201368.","journal-title":"Mol Cell"},{"key":"3093_CR26","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1084\/jem.20131735","volume":"210","author":"B Heizmann","year":"2013","unstructured":"Heizmann B, Kastner P, Chan S. Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. J Exp Med. 2013;210:2823\u201332.","journal-title":"J Exp Med"},{"key":"3093_CR27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood-2005-05-1935","volume":"107","author":"DT Teachey","year":"2006","unstructured":"Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2006;107:1149\u201355.","journal-title":"Blood"},{"key":"3093_CR28","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1182\/blood-2008-02-137752","volume":"113","author":"R Crazzolara","year":"2009","unstructured":"Crazzolara R, Cisterne A, Thien M, Hewson J, Baraz R, Bradstock KF, et al. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood. 2009;113:3297\u2013306.","journal-title":"Blood"},{"key":"3093_CR29","first-page":"291","volume":"20","author":"E Uli\u0144ska","year":"2016","unstructured":"Uli\u0144ska E, Mycko K, Sa\u0142aci\u0144ska-\u0141o\u015b E, Pastorczak A, Siwicka A, M\u0142ynarski W, et al. Impact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia \u2013 preliminary report. Contemp Oncol. 2016;20:291\u20136.","journal-title":"Contemp Oncol"},{"key":"3093_CR30","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1073\/pnas.0400063101","volume":"101","author":"MG Mohi","year":"2004","unstructured":"Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA. 2004;101:3130\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3093_CR31","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3390\/cancers13061359","volume":"13","author":"A El Hage","year":"2021","unstructured":"El Hage A, Dormond O. Combining mTOR inhibitors and T cell-based immunotherapies in cancer treatment. Cancers. 2021;13:1359.","journal-title":"Cancers"},{"key":"3093_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11060-019-03360-3","volume":"146","author":"SPC Hsu","year":"2020","unstructured":"Hsu SPC, Chen Y-C, Chiang H-C, Huang Y-C, Huang C-C, Wang H-E, et al. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors. J Neurooncol. 2020;146:417\u201326.","journal-title":"J Neurooncol"},{"key":"3093_CR33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jaci.2017.11.042","volume":"142","author":"R Ruiz-Garc\u00eda","year":"2018","unstructured":"Ruiz-Garc\u00eda R, Vargas-Hern\u00e1ndez A, Chinn IK, Angelo LS, Cao TN, Coban-Akdemir Z, et al. Mutations in PI3K110\u03b4 cause impaired natural killer cell function partially rescued by rapamycin treatment. J Allergy Clin Immunol. 2018;142:605\u2013.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"3093_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1158\/2326-6066.CIR-13-0046","volume":"1","author":"M Diken","year":"2013","unstructured":"Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, et al. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunol Res. 2013;1:386\u201392.","journal-title":"Cancer Immunol Res"},{"key":"3093_CR35","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","volume":"375","author":"S Maury","year":"2016","unstructured":"Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044\u201353.","journal-title":"N Engl J Med"},{"key":"3093_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27062","volume":"65","author":"AE Place","year":"2018","unstructured":"Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, et al. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65:e27062.","journal-title":"Pediatr Blood Cancer"},{"key":"3093_CR37","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-14-2888","volume":"21","author":"N Daver","year":"2015","unstructured":"Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, et al. A Phase I\/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed \/ refractory acute lymphoblastic leukemia. Clin Cancer Res J Am Assoc Cancer Res. 2015;21:2704\u201314.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"3093_CR38","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","volume":"3","author":"PB Johnston","year":"2016","unstructured":"Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, et al. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol. 2016;3:e309\u2013316.","journal-title":"Lancet Haematol"},{"key":"3093_CR39","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500\u20138.","journal-title":"Cancer Res"},{"key":"3093_CR40","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","volume":"8","author":"M Breuleux","year":"2009","unstructured":"Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira S-M, et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition. Mol Cancer Ther. 2009;8:742\u201353.","journal-title":"Mol Cancer Ther"},{"key":"3093_CR41","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1158\/1535-7163.MCT-14-0330","volume":"13","author":"E Rozengurt","year":"2014","unstructured":"Rozengurt E, Soares HP, Sinnet-Smith J. Suppression of feedback loops mediated by PI3K\/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther. 2014;13:2477\u201388.","journal-title":"Mol Cancer Ther"},{"key":"3093_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.isci.2018.06.006","volume":"5","author":"Y Yoneyama","year":"2018","unstructured":"Yoneyama Y, Inamitsu T, Chida K, Iemura S-I, Natsume T, Maeda T, et al. Serine phosphorylation by mTORC1 promotes IRS-1 degradation through SCF\u03b2-TRCP E3 ubiquitin ligase. iScience. 2018;5:1\u201318.","journal-title":"iScience"},{"key":"3093_CR43","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/blood-2006-06-030833","volume":"109","author":"Z Zeng","year":"2007","unstructured":"Zeng Z, Sarbassov DD, Samudio IJ, Yee KWL, Munsell MF, Ellen Jackson C, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007;109:3509\u201312.","journal-title":"Blood"},{"key":"3093_CR44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mc.20628","volume":"49","author":"X-G Chen","year":"2010","unstructured":"Chen X-G, Liu F, Song X-F, Wang Z-H, Dong Z-Q, Hu Z-Q, et al. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Mol Carcinog. 2010;49:603\u201310.","journal-title":"Mol Carcinog"},{"key":"3093_CR45","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.3324\/haematol.2021.278644","volume":"106","author":"V Sandova","year":"2021","unstructured":"Sandova V, Pavlasova GM, Seda V, Cerna KA, Sharma S, Palusova V, et al. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K\u03b4 inhibitor idelalisib. Haematologica. 2021;106:2995\u20139.","journal-title":"Haematologica"},{"key":"3093_CR46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","volume":"22","author":"M Skarzynski","year":"2016","unstructured":"Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salem D, et al. Interactions between ibrutinib and ANTi-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res J Am Assoc Cancer Res. 2016;22:86\u201395.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"3093_CR47","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood-2016-04-709519","volume":"128","author":"G Pavlasova","year":"2016","unstructured":"Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis. Blood. 2016;128:1609\u201313.","journal-title":"Blood"},{"key":"3093_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173770","volume":"134","author":"L Ondrisova","year":"2024","unstructured":"Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, et al. FoxO1\/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. J Clin Invest. 2024;134:e173770.","journal-title":"J Clin Invest"},{"key":"3093_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58868-2","volume":"16","author":"P Domizi","year":"2025","unstructured":"Domizi P, Sarno J, Jager A, Merchant M, Pacheco KZB, Yamada-Hunter SA, et al. IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies. Nat Commun. 2025;16:3800.","journal-title":"Nat Commun"},{"key":"3093_CR50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185489","volume":"135","author":"W Mu","year":"2025","unstructured":"Mu W, Tomer S, Harding J, Kedia N, Rezek V, Cook E, et al. Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo. J Clin Invest. 2025;135:e185489.","journal-title":"J Clin Invest"},{"key":"3093_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/imr.12845","volume":"295","author":"H Huang","year":"2020","unstructured":"Huang H, Long L, Zhou P, Chapman NM, Chi H. mTOR signaling at the crossroads of environmental signals and T-cell fate decisions. Immunol Rev. 2020;295:15\u201338.","journal-title":"Immunol Rev"},{"key":"3093_CR52","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1172\/JCI77746","volume":"125","author":"KN Pollizzi","year":"2015","unstructured":"Pollizzi KN, Patel CH, Sun I-H, Oh M-H, Waickman AT, Wen J, et al. mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. J Clin Invest. 2015;125:2090\u2013108.","journal-title":"J Clin Invest"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03093-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03093-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03093-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:47Z","timestamp":1793109767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03093-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3093"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03093-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All in vivo procedures were approved by the Local Ethics Committee of the University of Life Sciences, Warsaw, Poland (WAW2\/095\/2019, WAW2\/065\/2023). Informed written consent was obtained from all participants and\/or their parents.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}